Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy : influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment
PURPOSE: To evaluate the capacity of enriched CD34-positive (CD34+) progenitor cells to reconstitute hematopoiesis in poor-prognosis breast cancer patients following administration of a high-dose alkylating agent chemotherapy regimen.
PATIENTS AND METHODS: Forty-four breast cancer patients received high-dose chemotherapy followed by autologous bone marrow support (ABMS) with CD34+ hematopoietic progenitor cells in five sequentially treated cohorts. Following infusion of CD34+ marrow, cohort no. 1 received no growth factor, cohort no. 2 received granulocyte colony-stimulating factor (G-CSF), and cohort no. 3 received granulocyte-macrophage colony-stimulating factor (GM-CSF). Cohort no. 4 received the CD34+ fractions of both marrow and peripheral-blood progenitor cells (PBPCs) plus G-CSF. Cohort no. 5 received only the CD34+ PBPCs plus G-CSF. Immunohistochemical staining for breast cancer was performed on all hematopoietic cell products before and after the positive selection procedure, to assess quantitatively the level of tumor-cell contamination.
RESULTS: Cohorts no. 1, 2, 3, 4, and 5 achieved a granulocyte count > or = 500 x 10(9)/L in a median of 23, 10, 16, 11, and 11 days, with a platelet count greater than 20,000 x 10(9)/L documented in a median of 22, 23, 32, 12, and 10 days, respectively. The time to granulocyte reconstitution was significantly shorter for patients who received CD34+ PBPCs alone (cohort no. 5), or in combination with CD34+ marrow (cohort no. 4), when compared with those who received only the CD34+ marrow fraction (P < .01). From 1 to greater than 4 logs of breast cancer cell depletion were documented after CD34-selection, for patients in whom tumor was initially detected.
CONCLUSION: CD34+ marrow and/or PBPCs provide reliable and timely hematopoietic reconstitution in breast cancer patients receiving high-dose chemotherapy. Contamination of both marrow and PBPCs with breast cancer cells was reduced using this positive selection technique.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1994 |
|---|---|
| Erschienen: |
1994 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 12(1994), 1 vom: 01. Jan., Seite 28-36 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shpall, E J [VerfasserIn] |
|---|
| Themen: |
Antigens, CD |
|---|
| Anmerkungen: |
Date Completed 31.01.1994 Date Revised 10.02.2017 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM074821652 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM074821652 | ||
| 003 | DE-627 | ||
| 005 | 20231222023555.0 | ||
| 007 | tu | ||
| 008 | 231222s1994 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0250.xml |
| 035 | |a (DE-627)NLM074821652 | ||
| 035 | |a (NLM)7505806 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shpall, E J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy |b influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment |
| 264 | 1 | |c 1994 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.1994 | ||
| 500 | |a Date Revised 10.02.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: To evaluate the capacity of enriched CD34-positive (CD34+) progenitor cells to reconstitute hematopoiesis in poor-prognosis breast cancer patients following administration of a high-dose alkylating agent chemotherapy regimen | ||
| 520 | |a PATIENTS AND METHODS: Forty-four breast cancer patients received high-dose chemotherapy followed by autologous bone marrow support (ABMS) with CD34+ hematopoietic progenitor cells in five sequentially treated cohorts. Following infusion of CD34+ marrow, cohort no. 1 received no growth factor, cohort no. 2 received granulocyte colony-stimulating factor (G-CSF), and cohort no. 3 received granulocyte-macrophage colony-stimulating factor (GM-CSF). Cohort no. 4 received the CD34+ fractions of both marrow and peripheral-blood progenitor cells (PBPCs) plus G-CSF. Cohort no. 5 received only the CD34+ PBPCs plus G-CSF. Immunohistochemical staining for breast cancer was performed on all hematopoietic cell products before and after the positive selection procedure, to assess quantitatively the level of tumor-cell contamination | ||
| 520 | |a RESULTS: Cohorts no. 1, 2, 3, 4, and 5 achieved a granulocyte count > or = 500 x 10(9)/L in a median of 23, 10, 16, 11, and 11 days, with a platelet count greater than 20,000 x 10(9)/L documented in a median of 22, 23, 32, 12, and 10 days, respectively. The time to granulocyte reconstitution was significantly shorter for patients who received CD34+ PBPCs alone (cohort no. 5), or in combination with CD34+ marrow (cohort no. 4), when compared with those who received only the CD34+ marrow fraction (P < .01). From 1 to greater than 4 logs of breast cancer cell depletion were documented after CD34-selection, for patients in whom tumor was initially detected | ||
| 520 | |a CONCLUSION: CD34+ marrow and/or PBPCs provide reliable and timely hematopoietic reconstitution in breast cancer patients receiving high-dose chemotherapy. Contamination of both marrow and PBPCs with breast cancer cells was reduced using this positive selection technique | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Antigens, CD34 |2 NLM | |
| 650 | 7 | |a Colony-Stimulating Factors |2 NLM | |
| 700 | 1 | |a Jones, R B |e verfasserin |4 aut | |
| 700 | 1 | |a Bearman, S I |e verfasserin |4 aut | |
| 700 | 1 | |a Franklin, W A |e verfasserin |4 aut | |
| 700 | 1 | |a Archer, P G |e verfasserin |4 aut | |
| 700 | 1 | |a Curiel, T |e verfasserin |4 aut | |
| 700 | 1 | |a Bitter, M |e verfasserin |4 aut | |
| 700 | 1 | |a Claman, H N |e verfasserin |4 aut | |
| 700 | 1 | |a Stemmer, S M |e verfasserin |4 aut | |
| 700 | 1 | |a Purdy, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 12(1994), 1 vom: 01. Jan., Seite 28-36 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:1994 |g number:1 |g day:01 |g month:01 |g pages:28-36 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 1994 |e 1 |b 01 |c 01 |h 28-36 | ||